CRISPR Therapeutics (CRSP) and Sirius Therapeutics announced that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, a next-generation, long-acting Factor XI siRNA for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. SRSD107 is being co-developed by CRISPR Therapeutics and Sirius Therapeutics as part of a strategic collaboration to advance innovative treatments for cardiovascular and clotting-related diseases. The ongoing Phase 2 clinical trial is a randomized, multicenter, global study evaluating the safety and efficacy of SRSD107 for the prevention of VTE in patients undergoing TKA. The trial will assess the anticoagulant effects and pharmacological profile of SRSD107 and help inform dose selection for future pivotal studies, with the goal of confirming its potential as a differentiated approach for reducing thrombotic risk in patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics AG Surges Amid Analyst Praise
- Deckers, Credo, Crispr, AeroVironment, Abercrombie: Trending by Analysts
- Private Markets: Dyna Robotics raises $120M from Nvidia, Amazon
- Cathie Wood Invests $37M into Biotech Stocks, Trims Stake in KTOS, TEM, and ROKU Stocks
- Crispr Therapeutics AG: Promising Growth and Strategic Opportunities Justify Buy Rating